N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist.
N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide 3a was synthesized as an orally bioavailable agonist at MT1 and MT2 melatonin receptors with significantly low vasoconstrictive activity.
Sun
Li-Qiang
LQ
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA. sunl@bms.com
Takaki
Katherine
K
Chen
Jie
J
Iben
Lawrence
L
Knipe
Jay O
JO
Pajor
Lori
L
Mahle
Cathy D
CD
Ryan
Elaine
E
Xu
Cen
C
D000081:Acetamides / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000633:toxicity; D000284:Administration, Oral; D000818:Animals; D001572:Benzofurans / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000633:toxicity; D001682:Biological Availability; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D041681:NIH 3T3 Cells; D011869:Radioligand Assay; D051381:Rats; D044122:Receptor, Melatonin, MT1 / Q000819:agonists*; D044123:Receptor, Melatonin, MT2 / Q000819:agonists*; D013329:Structure-Activity Relationship
D000081:Acetamides; D001572:Benzofurans; C498372:N-(2-(2-(4-phenylbutyl)benzofuran-4-yl)cyclopropylmethyl)acetamide; D044122:Receptor, Melatonin, MT1; D044123:Receptor, Melatonin, MT2; D000242:Cyclic AMP